NFKB1 and breast carcinoma: In kind, some reports suggest that proteasome inhibitors exacerbated DOX-induced cytotoxicity in cardiomyocytes [38] and sensitized leukemia cells and breast cancer cells to DOX by suppressing NF-κB and activating JNK apoptosis signaling pathway [39, 40].